Abstracts - faqs.org

Abstracts

Health

Search abstracts:
Abstracts » Health

Effect of ACAT inhibition on the progression of coronary artherosclerosis

Article Abstract:

The enzyme acyl-coenzyme A:cholesterol acyltransferase (ACAT) Inhibitors was found to have antiatherosclerotic effects on some animal models. When ACAT inhibitor pactimibe was tested on 408 patients with coronary disease, it was found that ACAT inhibitor did not improve the primary efficacy variable (percent atheroma volume) and adversely affected two major secondary efficacy measures assessed by intravascular untrasonography.

Author: Pepine, Carl J., Brewer, H. Bryan, Ganz, Peter, Nissen, Steven E., Davidson, Michael H., Tuzcu, E. Murat, Schoenhagen, Paul, Sipahi, Ilke, Nicholls, Stephen J., Walters, David D., Crowe, Tim D., Deanfield, John E.
Publisher: Massachusetts Medical Society
Publication Name: The New England Journal of Medicine
Subject: Health
ISSN: 0028-4793
Year: 2006
Care and treatment, Development and progression, Atherosclerosis, Acetyl coenzyme A

User Contributions:

Comment about this article or add new information about this topic:

CAPTCHA


Nitroprusside in critically ill patients with left ventricular dysfunction and aortic stenosis

Article Abstract:

The drug nitroprusside may improve heart function in patients with severe aortic stenosis and heart failure while they wait for an aortic valve replacement, according to a study of 25 patients. Aortic stenosis occurs when the aortic valve in the heart becomes stiff and no longer functions properly. Nitroprusside belongs to a group of drugs called vasodilators because they dilate blood vessels.

Author: Francis, Gary S., Nissen, Steven E., Khot, Umesh N., Novaro, Gian M., Popovic, Zoran B., Mills, Roger M., Thomas, James D., Tuzcu, E. Murat, Hammer, Donald
Publisher: Massachusetts Medical Society
Publication Name: The New England Journal of Medicine
Subject: Health
ISSN: 0028-4793
Year: 2003
Evaluation, Drug therapy, Aortic valve stenosis, Sodium nitroferricyanide, Nitroprusside

User Contributions:

Comment about this article or add new information about this topic:

CAPTCHA


Statin therapy, LDL cholesterol, C-reactive protein and coronary artery disease

Article Abstract:

The reduced rate of progression of atherosclerosis associated with intensive Statin treatment is significantly related to greater reductions in the levels of both atherogenic lipoproteins and C-reactive protein (CRP). Statins have a wide range of biologic effects in addition to lipid lowering, including reducations in the levels of CRP.

Author: Nissen, Steven E., Tuzcu, E. Murat, O'Shaughnessy, Charles, Schoenhagen, Paul, Crowe, Tim, Ganz, Petre, Magorien, Raymond D., Sasiela, William J., Tsai, Jhon, Orazem, John
Publisher: Massachusetts Medical Society
Publication Name: The New England Journal of Medicine
Subject: Health
ISSN: 0028-4793
Year: 2005
Patient outcomes, Risk factors, Coronary heart disease, C-reactive protein, Statins

User Contributions:

Comment about this article or add new information about this topic:

CAPTCHA


Subjects list: Research, United States
Similar abstracts:
  • Abstracts: Effect of calcium supplementation on bone loss in postmenopausal women. Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis
  • Abstracts: Effect of advancing gestational age on the frequency of fetal ductal constriction in association with maternal indomethacin use
  • Abstracts: Effects of vesnarinone on morbidity and mortality of patients with heart failure. Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure
  • Abstracts: Influence of indomethacin on extracellular calcium homeostasis. Aggressive treatment in early rheumatoid arthritis: a randomised controlled trial
  • Abstracts: Effects of recombinant leptin therapy in a child with congenital leptin deficiency. Clinical spectrum of obesity and mutations in the melanocortin 4 receptor gene
This website is not affiliated with document authors or copyright owners. This page is provided for informational purposes only. Unintentional errors are possible.
Some parts © 2025 Advameg, Inc.